4
Changes in Ownership
Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000115
Director sold 18,000 shares at an average $104.93 ($1,888,749)
- Director acquired 18,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
BALL KRISTINE M · Director
Table I: Non-derivative
7 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-11-12 | Exercise or conversion : show line 1 in the form 10b5-1 | +18,000 | $6.84 | $123,120 | 18,000 | D |
| 2026-11-12 | Sale : show line 2 in the form 10b5-1 | −1,196 | $102.10 | $122,108 | 16,804 | D |
| 2026-11-12 | Sale : show line 3 in the form 10b5-1 | −1,300 | $103.09 | $134,021 | 15,504 | D |
| 2026-11-12 | Sale : show line 4 in the form 10b5-1 | −2,039 | $104.16 | $212,387 | 13,465 | D |
| 2026-11-12 | Sale : show line 5 in the form 10b5-1 | −10,765 | $105.31 | $1,133,706 | 2,700 | D |
| 2026-11-12 | Sale : show line 6 in the form 10b5-1 | −2,500 | $106.05 | $265,130 | 200 | D |
| 2026-11-12 | Sale : show line 7 in the form 10b5-1 | −200 | $106.99 | $21,397 | 0 | D |
| Open-market sales · 18,000 sh · avg $104.93 · $1,888,749 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-11-12 | Exercise or conversion : show line 8 in the form 10b5-1 Stock Option (Right to Buy) | −18,000 | 53,426 | D |
Loading xslF345X06/form4.xml…